Medical imaging software company MIM Software Inc reported on Wednesday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) for molecular radiotherapy (MRT) dosimetry to target tumors.
The company said MRT is an effective form of therapy that uses radiopharmaceuticals including Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express.
In conjunction, MIM SurePlan MRT provides both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by utilizing the patient's own images, allowing for personalized dosimetry measurements. MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry for molecular radiotherapy. The other features include multi-tracer theranostics support, quantitative SPECT and planar corrections and dosimetry reporting tools, added the company.
From 18-19 January 2019, the company will demonstrate MIM SurePlan MRT at the SNMMI 2019 Mid-Winter Meeting in Palm Springs, CA.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117